IOVANCE BIOTHERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 6Avg age 57Avg tenure 6.5y
FV
Frederick Vogt
Chief Executive Officer
Age 52Since 2021-06-17Profile →
+10
Executives5
FV
Frederick Vogt→
Chief Executive Officer
Age 52Since 2021-06-17
CR
Corleen Roche→
Director of Finance/CFO
Age 60Since 2025-08-05
BS
Brian Shew→
Chief Tech/Sci/R&D Officer
—Since 2021-06-30
IB
Igor Bilinsky→
Chief Operating Officer
Age 53Since 2021-03-14
FF
Friedrich Finckenstein→
Chief Tech/Sci/R&D Officer
Age 59Since 2019-07-17
Board of directors6
RM
Ryan Maynard→
Director/Board Member
Age 56Since 2015-02-15
WR
Wayne P. Rothbaum→
Director/Board Member
Age 58Since 2016-06-06
ID
Iain Dukes→
Chairman
Age 67Since 2016-08-15
MW
Michael Weiser→
Director/Board Member
Age 63Since 2018-03-14
FV
Frederick Vogt→
Director/Board Member
Age 52Since 2024-06-10
AC
Athena Countouriotis→
Director/Board Member
Age 54Since 2019-06-09
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| MHR Fund Management LLC /Private Equity/ | 6.488 % | 28,967,103 |
| MHR Fund Management LLC | 6.488 % | 28,967,103 |
| BlackRock Advisors LLC | 6.39 % | 28,532,332 |
| Quogue Capital LLC | 6.286 % | 28,067,333 |
| STATE STREET CORPORATION | 3.908 % | 17,448,108 |
Catalog · 2026-07-09
Registry officers11
| Name | Role | Since | Shares |
|---|---|---|---|
| Brian Shew | Chief Tech/Sci/R&D Officer | 2021-06-30 | - |
| Corleen Roche | Director of Finance/CFO | 2025-08-05 | - |
| Frederick Vogt | Chief Executive Officer | 2021-06-17 | - |
| Friedrich Finckenstein | Chief Tech/Sci/R&D Officer | 2019-07-17 | - |
| Iain Dukes | Chairman | 2016-08-15 | - |
| Igor Bilinsky | Chief Operating Officer | 2021-03-14 | - |
| Athena Countouriotis | Director/Board Member | 2019-06-09 | - |
| Frederick Vogt | Director/Board Member | 2024-06-10 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 14.4Range 7–20Analysts 10
7Mean 14.420
- Strong buy 2
- Buy 6
- Hold 2
Broker actions40 of 157
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | 18 | 2026-10-13 |
| Baird | Maintained | Neutral | 11 | 2026-10-08 |
| Wells Fargo | Maintained | Overweight | 18 | 2026-09-30 |
| HC Wainwright & Co. | Maintained | Buy | 20 | 2026-09-29 |
| Barclays | Maintained | Overweight | 15 | 2026-09-17 |
| TD Cowen | Maintained | Buy | 10 | 2026-08-25 |
| UBS | Maintained | Neutral | 7 | 2026-08-20 |
| Mizuho | Maintained | Outperform | 11 | 2026-08-18 |
| Barclays | Maintained | Overweight | 13 | 2026-08-07 |
| Citizens | Maintained | Market Outperform | 8 | 2026-08-07 |
| Chardan Capital | Maintained | Buy | 14 | 2026-05-08 |
| Chardan Capital | Maintained | Buy | 16 | 2026-04-10 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.